S&P Futures
3,623.75-12.75(-0.35%)Dow Futures
29,717.00-157.00(-0.53%)Nasdaq Futures
12,263.50+6.00(+0.05%)
Kodiak Sciences Inc. (KOD)
- Barrons.com
Kodiak Sciences, Playa Hotel See Activist Action
Baker Brothers Advisors raised its stake in biopharmaceutical firm Kodiak Sciences. Farallon Capital halved its investment in hotel and resort operator Playa Hotel.
- PR Newswire
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the closing of its previously announced underwritten public offering of 5,972,222 shares of its common stock, which includes 778,985 shares sold pursuant to the underwriters' exercise in full of their option to purchase additional shares, at a price to the public of $108.00 per share. The aggregate gross proceeds from the offering were approximately $645.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences.
- PR Newswire
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced the pricing of an underwritten public offering of 5,193,237 shares of its common stock at a price to the public of $108.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $560.9 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Kodiak Sciences. The offering is expected to close on or about November 20, 2020, subject to customary closing conditions. In addition, Kodiak Sciences has granted the underwriters a 30-day option to purchase up to an additional 778,985 shares of its common stock at the public offering price, less underwriting discounts and commissions.
